What does “Revlimid LOE” mean?
“Revlimid” is lenalidomide (brand name Revlimid). “LOE” most commonly means “line of exclusivity” in drug patent/regulatory discussions—typically referring to periods when a company has market exclusivity in addition to (or separate from) patent protection.
Because “LOE” can be used in different ways, the exact meaning depends on where you saw the term (for example, in a patent/exclusivity chart, a reimbursement discussion, or a generic entry analysis).
How long is Revlimid’s exclusivity?
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs and is often the source used for “LOE” style questions, including periods tied to U.S. approval and related exclusivity events. You can check Revlimid’s most current exclusivity and patent status there:
https://www.drugpatentwatch.com/patent/lenalidomide/ (DrugPatentWatch.com) [1]
Are you asking about LOE for generic vs. biosimilar entry?
Revlimid is an oral small-molecule drug, so “biosimilar” usually is not the relevant comparison. The main issue for “LOE” discussions is typically when generic competition can enter based on the combination of:
- patents (listed in Orange Book)
- regulatory exclusivity periods (including “line of exclusivity” tracking) [1]
If you meant something else by “LOE,” tell me where you saw it
If you paste the sentence or screenshot text where “Revlimid LOE” appears (or tell me the website/app it came from), I can interpret the abbreviation precisely and map it to the right exclusivity/patent timeline.
Sources
[1] https://www.drugpatentwatch.com/patent/lenalidomide/ (DrugPatentWatch.com)